Pharmacodynamics of D-mannose in the prevention of recurrent urinary infections

Arianna Pani1, Lucini Valeria1, Silvana Dugnani1

  • 1Department of Oncology and Onco-Hematology, University of Milan, Milan, Italy.

Insights

D-mannose effectively prevents recurring urinary tract infections (rUTIs) by inhibiting E. coli adhesion and invasion. This study provides a pharmacological basis for optimal D-mannose dosage in rUTI prevention strategies.

Area of Science:

  • Urology
  • Microbiology
  • Pharmacology

Background:

  • Recurring urinary tract infections (rUTIs) are often caused by Escherichia coli.
  • E. coli invades urothelial cells, forming bacterial reservoirs.
  • D-mannose is a potential agent for rUTI prevention, but optimal dosage is unclear.

Purpose of the Study:

  • To determine the effective dosage of D-mannose for preventing E. coli adhesion and invasion.
  • To provide a pharmacological basis for D-mannose dosing in rUTI prevention.

Main Methods:

  • Selected E. coli strains based on adhesion capacity.
  • Tested anti-adhesive and anti-invasion efficacy using TCC-5637 urothelial cells.
  • Evaluated D-mannose's biofilm interference.

Main Results:

  • The IC50 for D-mannose's anti-adhesive efficacy was 0.51 mg/ml.
  • The IC50 for D-mannose's anti-invasion activity was 0.30 mg/ml.
  • D-mannose inhibited E. coli adhesion at high concentrations and invasion at lower concentrations. Biofilm interference was observed at 50 mg/ml.

Conclusions:

  • D-mannose demonstrates concentration-dependent inhibition of E. coli adhesion and invasion.
  • Lower concentrations of D-mannose are effective in inhibiting bacterial invasion.
  • Findings support D-mannose as a viable agent for rUTI prevention with specific dosage recommendations.

Related Concept Videos

Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care01:30

Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care

A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...
56
Urinary Tract Infection IV: Nursing Management01:17

Urinary Tract Infection IV: Nursing Management

In managing urinary tract infections (UTIs) in nursing, a comprehensive assessment is essential. Begin by gathering subjective data, such as the patient’s complaints of dysuria (painful urination), urinary frequency, urgency, suprapubic pain, and any lower abdominal discomfort. This information can be complemented by questions regarding previous UTIs, sexual activity, and personal hygiene practices, which can provide insight into risk factors. Objective assessment should focus on signs...
108
Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
575
Urinary Tract Infection II: Pathophysiology01:25

Urinary Tract Infection II: Pathophysiology

The pathophysiology of urinary tract infections (UTIs) encompasses several progressive stages, beginning with bacterial colonization and culminating in potential systemic complications if untreated. UTIs are primarily initiated by bacteria, such as Escherichia coli, which often originate from the gastrointestinal tract and migrate to the urinary system through the periurethral area. This migration can occur via several routes, including improper hygiene practices, sexual activity, or...
64
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
293
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
334